| 7.32 -0.03 (-0.41%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.22  |
1-year : | 10.64 |
| Resists | First : | 7.89 |
Second : | 9.1 |
| Pivot price | 6.88 |
|||
| Supports | First : | 5.94 | Second : | 4.94 |
| MAs | MA(5) : | 7.01 |
MA(20) : | 6.86 |
| MA(100) : | 17.5 |
MA(250) : | 132.68 |
|
| MACD | MACD : | -0.8 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 63.8 |
| RSI | RSI(14): 44.5 | |||
| 52-week | High : | 1382.4 | Low : | 5.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ APVO ] has closed below upper band by 9.2%. Bollinger Bands are 84.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.61 - 7.64 | 7.64 - 7.67 |
| Low: | 7.01 - 7.04 | 7.04 - 7.07 |
| Close: | 7.3 - 7.35 | 7.35 - 7.41 |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Thu, 19 Feb 2026
Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks
Wed, 04 Feb 2026
Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail
Fri, 09 Jan 2026
Biotech lines up $60M to keep next-wave cancer drugs moving to 2029 - Stock Titan
Mon, 29 Dec 2025
Aptevo Therapeutics To Implement 1-for-18 Reverse Stock Split - Nasdaq
Fri, 26 Dec 2025
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split - ACCESS Newswire
Tue, 09 Dec 2025
Aptevo’s AML therapy shows strong safety profile in phase 1b/2 trial - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 935440 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 140 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -79.2 % |
| Return on Equity (ttm) | -242.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 233108 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.78851e+007 |
| Qtrly Earnings Growth | 758.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | 1.04 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.47 |
| Dividend | 0 |
| Forward Dividend | 152190 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|